Fundz

Watching CervoMed Inc.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Reg FD DisclosureItem 7.01 · 8-KLOW RiskPositive

CervoMed Inc.

diffusionpharma.com
Filed: Jul 9, 2026Boston, MassachusettsCIK: 0001053691Healthcare
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

CervoMed Inc. announced completion of enrollment in its Phase 2a clinical study of neflamapimod for treating nonfluent variant primary progressive aphasia (a type of frontotemporal dementia), marking a significant milestone in the drug's development and de-risking the path toward potential commercialization.

Key Takeaways

Enrollment completion in Phase 2a study represents a major clinical development milestone for neflamapimod, reducing execution risk

The drug targets nonfluent variant primary progressive aphasia, a rare neurodegenerative disease with significant unmet medical needs

1 more takeaway

Related Filings (1)

1 more filing from CervoMed Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateJul 9, 2026
Item7.01
CategoryReg FD Disclosure
CIK0001053691
Accession #crvo20260709_8k.htm
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
product launchregulatory

What This Means

The company is making a public disclosure under Regulation FD, often sharing material information to ensure equal access.
View Full Filing on SEC.govBrowse More Filings

CervoMed Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.